DDAVP® Injection (desmopressin acetate) 4 µg/mL is a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation.
DDAVP® Injection is indicated for the following:
DDAVP Injection 4 µg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%.
DDAVP will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure.
DDAVP will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding.
DDAVP is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies.
In certain clinical situations, it may be justified to try DDAVP in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored.
von Willebrand's Disease (Type I):
DDAVP Injection 4 µg/mL is indicated for patients with mild to moderate classic von Willebrand's disease (Type I) with factor VIII levels greater than 5%. DDAVP will often maintain hemostasis in patients with mild to moderate von Willebrand's disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure.
DDAVP will usually stop bleeding in mild to moderate von Willebrand's patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding.
Those von Willebrand's disease patients who are least likely to respond are those with severe homozygous von Willebrand's disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of DDAVP to ensure that adequate levels are being achieved.
DDAVP is not indicated for the treatment of severe classic von Willebrand's disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen. (See WARNINGS.)
Diabetes Insipidus: DDAVP Injection 4 µg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. DDAVP is ineffective for the treatment of nephrogenic diabetes insipidus.
DDAVP is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate. These include poor intranasal absorption, nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery.
Media Articles Related to Ddavp Injection (Desmopressin)
FDA Panel Backs Nasal Spray for Nocturnal Polyuria
Source: MedPage Today OB/Gyn [2016.10.19]
(MedPage Today) -- Support for intransal desmopressin despite reservations
Published Studies Related to Ddavp Injection (Desmopressin)
Desmopressin and oxybutynin in monosymptomatic nocturnal enuresis: a randomized,
double-blind, placebo-controlled trial and an assessment of predictive factors. 
evaluated... CONCLUSIONS: Our findings highlight that anticholinergic agents may play an
Efficacy and safety of desmopressin for treatment of nocturia: a systematic review and meta-analysis of double-blinded trials. [2011.09.07]
PURPOSE: The purpose of this analysis was to evaluate the efficacy and safety of desmopressin for the treatment of nocturia... CONCLUSIONS: Administered desmopressin was an effective and well-tolerated treatment for nocturia.
Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial. [2011.06]
BACKGROUND: Bleeding complications occur in one-third of percutaneous kidney biopsies and increase costs of the hospital stay. The aim of the study was to evaluate the effect of prebiopsy administration of desmopressin acetate versus placebo in the incidence of postbiopsy bleeding complications... CONCLUSIONS: Prebiopsy desmopressin administration decreases the risk of bleeding and hematoma size in patients undergoing percutaneous kidney biopsy without a cost increase. Copyright (c) 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Patients with severe aortic valve stenosis and impaired platelet function benefit from preoperative desmopressin infusion. [2011.05]
BACKGROUND: Patients with severe aortic valve stenosis have a markedly reduced platelet function as measured by a prolonged collagen adenosine diphosphate closure time (CADP-CT) determined by the platelet function analyzer PFA-100. We hypothesized that such patients may benefit from desmopressin when they present with prolonged CADP-CT due to the specific action of desmopressin on von Willebrand factor (VWF) and CADP-CT... CONCLUSIONS: Prolonged CADP-CT indicates platelet dysfunction in severe aortic valve stenosis, and can guide the use of desmopressin as an effective prohemostatic agent in patients with severe aortic valve stenosis. Copyright (c) 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
Desmopressin as a pharmacological tool in vasopressinergic hypothalamus-pituitary-adrenal axis modulation: neuroendocrine, cardiovascular and coagulatory effects. [2011.03]
Arginine-vasopressin (AVP) is a physiological co-activator of the hypothalamus-pituitary-adrenal (HPA) axis, together with corticotrophin releasing hormone (CRH)... A 10 mug dDAVP bolus is considered a safe vasopressinergic function test at which no confounding effects of systemic or autonomic stress were seen.
Clinical Trials Related to Ddavp Injection (Desmopressin)
DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty [Not yet recruiting]
This is study looking at the use of a medication, Desmopressin acetate (DDAVP), to reduce
bleeding, swelling, and bruising in patients undergoing cosmetic nose surgery. DDAVP is a
drug used in patients with bleeding disorders. It works by activating molecules in the
blood stream called platelets that promote clotting. In the study, participants who are
have cosmetic nose surgery (rhinoplasty) will be randomly assigned to receive or not receive
medication. Photographs taken before and shortly after surgery will be evaluated for the
amount of bruising and swelling. Patients with heart, lung, kidney, or liver problems are
not eligible to participate.
Efficacy and Safety of IL-11 in DDAVP Unresponsive [Completed]
The purpose of this study is to determine the biologic efficacy and safety of rhIL-11 when
given subcutaneously in adults with moderate or mild hemophilia A or Von Willebrand disease
unresponsive to DDAVP. Biologic efficacy will be measured by the number and percent increase
of VWD coagulation tests (FVIII: C, VWF: Ag, VWF: RCo, closure time, APTT, and VWF multimers)
to the normal range, or at least to 1. 5-3 time baseline, following dosing of rhIL-11 when
given daily for 4 days, and boosted by DDAVP infusion on day 4, in those in whom DDAVP is
not contraindicated. Safety will be measured by the frequency of adverse events, including
fever, headache, fatigue, myalgias, arthralgias, fluid retention, or edema.
Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers [Enrolling by invitation]
The purpose of this study is to determine how female hemophilia A carriers respond to a
medication called DDAVP (Desmopressin).
The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion [Completed]
There is substantial evidence that women throughout life have significantly lower plasma
levels of the antidiuretic hormone vasopressin (pAVP) compared to men. The importance of
this is not yet fully elucidated, but in relation to the observations of lower pAVP levels,
no significant difference in renal response parameters was found. This could be interpreted
an increased renal sensitivity in females compared to males. The theory of increased renal
sensitivity in females is supported by a few pharmacodynamic studies currently available on
this topic. However none of the studies was designed with the purpose of investigate the
The aim of this study is to investigate possible gender differences in the renal sensitivity
to dDAVP and the effect of age on these differences. This will be done by low dose graded
infusion of the synthetic AVP analog dDAVP.
Participants are 80 healthy volunteers equally distributed between four age groups, 8-10
years of age, 16-18 years of age, 25-40 years og age and 65+ years of age.
Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept [Completed]
The investigators intend to show that DDAVP improves platelet activity from baseline to 60
minutes after treatment start.
Page last updated: 2016-10-19